Ironwood Pharmaceuticals (IRWD) Other Non-Current Liabilities (2011 - 2026)

Ironwood Pharmaceuticals has disclosed Other Non-Current Liabilities across 15 years of filings, most recently posting $21.2 million for Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $21.2 million, up 22.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $21.2 million (up 22.43% YoY), and the FY2025 annual result was $21.6 million, up 26.56% from the prior year.
• Other Non-Current Liabilities came in at $21.2 million for Q1 2026 at Ironwood Pharmaceuticals, down from $21.6 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $39.8 million in Q3 2024 to a low of $5.1 million in Q1 2022.
• The 5-year median for Other Non-Current Liabilities is $21.6 million (2025), against an average of $21.1 million.
• Across the five-year window, Other Non-Current Liabilities jumped 478.86% in 2022 and sank 44.14% in 2025, its largest moves.
• Ironwood Pharmaceuticals' Other Non-Current Liabilities stood at $9.8 million in 2022, then jumped by 190.96% to $28.4 million in 2023, then sank by 39.8% to $17.1 million in 2024, then increased by 26.56% to $21.6 million in 2025, then decreased by 2.21% to $21.2 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $21.2 million (Q1 2026), $21.6 million (Q4 2025), and $22.2 million (Q3 2025), per Business Quant data.